BioWorld

Feb. 21, 2007

Shire Buying Vyvanse Partner New River For $64 Per Share

Shire plc, which partnered with New River Pharmaceuticals Inc. two years on a drug for attention deficit hyperactivity disorder, agreed to acquire the smaller firm for $2.6 billion in cash. (BioWorld Today) Read More

Lux Starts Phase III Studies; Isotechnika Raises $34.5M

New Autism Clues As Prevalence Estimates Increase Once Again

Caprion, Ecopia Merger Gets $45M Pledge From Investors

Theratechnologies Bringing In C$52.5M To Fund Phase III Trial

BioMarin Pharma Misses With Phase IIa Hypertension Trial

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for Dec. 10, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 10, 2025.

Medline plans record-setting $5.37B IPO

BioWorld MedTech

Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...

US lawmakers demand that Kennedy be held accountable

BioWorld

As the systematic dismantling of the U.S. vaccine schedule escalates, the demands to hold Health and Human Services Secretary Robert Kennedy accountable are...

Heartbeam wins appeal, gains FDA clearance

BioWorld MedTech

Management is beaming with delight at Heartbeam Inc. as the company's appeal strategy paid off with U.S. FDA clearance for its synthetic 12-lead electrocardiogram...